Home › Agent Hub › Agent Tools › Part D coverage by drug › Skyrizi

Agent Tools

Skyrizi Part D coverage 2027

Skyrizi is a brand of risankizumab. What agents check before quoting it: how many 2027 Part D plans cover it, on which tier, with what restrictions and copays, by plan type, carrier and state.

Coverage at a glance

In 2027, 5,386 of 5,492 Medicare Part D and Medicare Advantage drug plans (98.1%) list Skyrizi on their formulary, across 273 of 286 formularies. The most common placement is tier 5 (5,217 plans, 96.9% of those covering it). 5,283 of the covering plans require prior authorization (98.1%), 0 step therapy and 5,117 a quantity limit.

What a 30-day fill costs

51 covering plans charge a flat copay for a 30-day supply at a preferred retail pharmacy after the deductible — median $0, 51 of them $0; 5,335 charge coinsurance instead — median 26% of the drug's cost. Once a member's out-of-pocket drug spending reaches $2,400 in 2027, covered drugs cost $0 for the rest of the year.

What changed since 2026

2026: 5,413 of 5,496 plans covered it (98.5%); 2027: 5,386 of 5,492 (98.1%).

Of 4,367 plans offered in both years, 20 added it to the formulary and 59 dropped it.

Among plans covering it both years, 42 moved it to a higher tier and 7 to a lower one; 0 added prior authorization and 0 removed it.

Tier placement

By plan type

By carrier

By state

Medicare usage

Medicare Part D paid for 217,953 30-day fills of Skyrizi in 2024 for about 26,993 enrollees, at an average total cost of $8,143.66 per 30-day fill (CMS Part D Prescribers by Geography and Drug, national).

Counts are over every Medicare Advantage drug plan and stand-alone Part D plan in the CMS monthly formulary files, excluding employer plans. A plan counts as covering a drug when any strength or form of it is on the plan’s formulary; the tier, prior authorization, step therapy and quantity limit shown are the most favorable version on that formulary. Copays are for a 30-day supply at a preferred retail pharmacy after the deductible. This is a reference for licensed agents, not a plan recommendation; verify with the plan’s formulary before advising a client. Source: CMS Part D formulary files (release 10/08/2026). CMS formulary data.